Regeneron Pharmaceuticals, Inc. (REGN) Up 4.6% — Should I Ride This Strength Higher?
Key Points
Regeneron Pharmaceuticals, Inc. (REGN) extended its strong performance in the latest session, with shares advancing 4.63% to close at $812.49. That move represents a gain of $35.95 from the prior close of $776.54, underscoring bullish activity as the stock pushes firmly higher. Trading volume reached 819,299 shares, somewhat below the 90-day average of 1,024,305, suggesting that the latest surge came without unusually heavy turnover. Even so, the price action was decisive, marking a clear upward shift in investor positioning.
Today’s close also places REGN solidly above its recent milestone, as it finished above its 52-week high of $792.77 set on Dec. 24, 2025. The stock is now trading roughly $19.72 above that prior peak, signaling that buyers are gaining ground and extending the uptrend into new high territory. Within the broader large-cap healthcare group, this move stands out: While peers such as Eli Lilly (LLY), Johnson & Johnson (JNJ), AbbVie (ABBV), UnitedHealth Group (UNH), and Merck (MRK) have all experienced periods of strength over the past year, REGN’s latest breakout to fresh highs highlights especially strong momentum in the current tape. Overall, the price action points to a stock that is surging ahead of its recent range and reinforcing a constructive technical backdrop.
Why Regeneron Pharmaceuticals, Inc. Price is Moving Higher
Regeneron’s latest leg higher is being driven by a clear wave of positive catalysts and growing investor enthusiasm. The stock’s push to a new 52-week high on Jan. 7, 2026, came immediately after Bank of America upgraded shares to Buy with a sharply higher $860 target and Citi lifted its target to $900. Additional target hikes from firms such as Canaccord and Guggenheim have reinforced a broadly positive Wall Street stance, underpinned by a recent earnings beat ($11.83 EPS vs. $9.73 expected) and a Moderate Buy consensus. A positive Earnings ESP of +8.68% heading into the Jan. 30 report adds to the perception that fundamentals are still running ahead of expectations, encouraging momentum-oriented and fundamentally driven investors alike.
Under the surface, the price strength reflects confidence in Regeneron’s product and pipeline execution. Recent FDA approval of Eylea HD for retinal vein occlusion, along with label expansions for Dupixent, is helping offset modest top-line growth while supporting a robust profit margin above 30%. At the same time, the new gene editing partnership with Tessera Therapeutics, including a 50:50 cost and profit share on TSRA-196 for AATD, signals a strategic push into next-generation genetic medicines that investors view as a longer-term growth engine. Against a strong backdrop for large-cap biotech and pharma names such as Eli Lilly, Johnson & Johnson, AbbVie, UnitedHealth Group, and Merck, Regeneron’s 41% six-month surge stands out, suggesting the market is rewarding its combination of durable cash-generating franchises and emerging high-upside programs.
What is the Regeneron Pharmaceuticals, Inc. Rating - Should I Buy?
Weiss Ratings assigns REGN a C rating. Current recommendation is Hold. In practical terms, that places Regeneron Pharmaceuticals, Inc. in the middle of the pack from a risk/reward standpoint — neither a standout Buy nor a stock to avoid outright. For investors, a C rating often signals a name worth watching closely, particularly when underlying business quality looks stronger than recent stock performance.
What stands out most for REGN is operational strength. The Excellent Efficiency Index and Excellent Solvency Index indicate a well-managed balance sheet and effective use of capital. A profit margin of 32.13% and return on equity of 15.19% support the view that Regeneron converts its revenue into earnings efficiently, even with modest revenue growth of 0.90%. A forward P/E of 18.59 appears reasonable for a profitable Health Care company with this level of profitability and balance sheet quality.
On the other hand, the reward side of the equation is tempered by a Weak Total Return Index, Weak Volatility Index, and Weak Dividend Index. That combination suggests REGN’s recent share performance and risk profile have not kept pace with higher-rated peers, and it offers limited income appeal. Within the Health Care sector, Eli Lilly and Company (LLY, B) and Johnson & Johnson (JNJ, B) earn Buy-level ratings, while AbbVie Inc. (ABBV, C) and Merck & Co., Inc. (MRK, C) sit alongside Regeneron in Hold territory.
Taken together, Regeneron’s C (Hold) rating captures a company with high-quality operations and financial strength, but a stock that has yet to consistently translate those strengths into superior, risk-adjusted returns.
About Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc. (REGN) is a biotechnology company in the Health Care sector focused on discovering, developing and commercializing medicines for serious medical conditions. Founded in 1988 and headquartered in Tarrytown, New York, the company has built its business around proprietary genetic and antibody technologies that support a broad pipeline of therapeutic candidates. Regeneron is known for its strengths in ophthalmology, immunology, oncology, cardiovascular and inflammatory diseases, where its therapies target well-defined biological pathways with the aim of delivering differentiated clinical outcomes.
A central competitive advantage for Regeneron is its integrated research and development platform, which includes its VelociSuite technologies for antibody discovery and development, and its large-scale genetics initiative, Regeneron Genetics Center. These capabilities enable the company to move from target identification to clinical candidate efficiently, supporting a steady flow of new biologic therapies and next-generation antibodies. Regeneron’s marketed products include treatments for retinal diseases, allergic conditions, atopic dermatitis, asthma and other inflammatory disorders, as well as therapies in oncology and rare diseases, often developed in collaboration with leading global pharmaceutical partners.
Within the Pharmaceuticals, Biotechnology and Life Sciences industry, Regeneron is recognized for its scientific depth and focus on high-need therapeutic areas. Its portfolio strategy emphasizes biologics and precision medicine, leveraging human genetics to better understand disease and guide drug development. This combination of advanced antibody engineering, large-scale genomic analysis and in-house manufacturing provides the company with notable control over the drug development lifecycle and supports its position as a key innovator in biologic therapies.
Investor Outlook
With Regeneron Pharmaceuticals, Inc. (REGN) carrying a C (Hold) Weiss Rating, investors may see potential for continued gains if the company can sustain its operational momentum and sector leadership. The key will be how stock trades around recent support and resistance levels, as well as how broader Health Care trends and future rating changes unfold. See full rankings of all C-rated Health Care stocks inside the Weiss Stock Screener.
--